 JUPITER, Fla., April 04, 2022 GLOBE NEWSWIRE -- Dyadic International, Inc. Dyadic, or the Company NASDAQ: DYAI a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its management and representatives will be presenting at the following scientific medical meetings: 